|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Omura G, Blessing JA, Ehrlich CE, Miller
A, Yordan E, Creasman WT and Homesley HD: A randomized trial of
cyclophosphamide and doxorubicin with or without cisplatin in
advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
Cancer. 57:1725–1730. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Omura GA, Bundy BN, Berek JS, Curry S,
Delgado G and Mortel R: Randomized trial of cyclophosphamide plus
cisplatin with or without doxorubicin in ovarian carcinoma: A
Gynecologic Oncology Group Study. J Clin Oncol. 7:457–465.
1989.PubMed/NCBI
|
|
4
|
Aabo K, Adams M, Adnitt P, Alberts DS,
Athanazziou A, Barley V, Bell DR, Bianchi U, Bolis G, Brady MF, et
al: Chemotherapy in advanced ovarian cancer: Four systematic
meta-analyses of individual patient data from 37 randomized trials.
Advanced Ovarian Cancer Trialists' Group. Br J Cancer.
78:1479–1487. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Trimbos JB, Parmar M, Vergote I, Guthrie
D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli
S, et al: European Organisation for Research and Treatment of
Cancer Collaborators - Adjuvant ChemoTherapy In Ovarian Neoplasm:
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant
ChemoTherapy In Ovarian Neoplasm trial: Two parallel randomized
phase III trials of adjuvant chemotherapy in patients with
early-stage ovarian carcinoma. J Natl Cancer Inst. 95:105–112.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bookman MA: Developmental chemotherapy and
management of recurrent ovarian cancer. J Clin Oncol. 21(Suppl 10):
149s–167s. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Modesitt SC and Jazaeri AA: Recurrent
epithelial ovarian cancer: Pharmacotherapy and novel therapeutics.
Expert Opin Pharmacother. 8:2293–2305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Biedler JL and Riehm H: Cellular
resistance to actinomycin D in Chinese hamster cells in vitro:
Cross-resistance, radioautographic, and cytogenetic studies. Cancer
Res. 30:1174–1184. 1970.PubMed/NCBI
|
|
9
|
Fojo A, Hamilton TC, Young RC and Ozols
RF: Multidrug resistance in ovarian cancer. Cancer. 60(Suppl):
2075–2080. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scheffer GL, Schroeijers AB, Izquierdo MA,
Wiemer EA and Scheper RJ: Lung resistance-related protein/major
vault protein and vaults in multidrug-resistant cancer. Curr Opin
Oncol. 12:550–556. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Teodori E, Dei S, Martelli C, Scapecchi S
and Gualtieri F: The functions and structure of ABC transporters:
Implications for the design of new inhibitors of Pgp and MRP1 to
control multidrug resistance (MDR). Curr Drug Targets. 7:893–909.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roy S, Kenny E, Kennedy S, Larkin A,
Ballot J, De Perez Villarreal M, Crown J and O'Driscoll L:
MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in
non-small cell lung cancer. Anticancer Res. 27:1325–1330.
2007.PubMed/NCBI
|
|
13
|
Ahmad A, Robinson AR, Duensing A, van
Drunen E, Beverloo HB, Weisberg DB, Hasty P, Hoeijmakers JH and
Niedernhofer LJ: ERCC1-XPF endonuclease facilitates DNA
double-strand break repair. Mol Cell Biol. 28:5082–5092. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arora S, Kothandapani A, Tillison K,
Kalman-Maltese V and Patrick SM: Downregulation of XPF-ERCC1
enhances cisplatin efficacy in cancer cells. DNA Repair. 9:745–753.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim R, Tanabe K, Uchida Y, Emi M, Inoue H
and Toge T: Current status of the molecular mechanisms of
anticancer drug-induced apoptosis. The contribution of
molecular-level analysis to cancer chemotherapy. Cancer Chemother
Pharmacol. 50:343–352. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Johnstone RW, Cretney E and Smyth MJ:
P-glycoprotein protects leukemia cells against caspase-dependent,
but not caspase-independent, cell death. Blood. 93:1075–1085.
1999.PubMed/NCBI
|
|
17
|
Maugeri-Saccà M, Vigneri P and De Maria R:
Cancer stem cells and chemosensitivity. Clin Cancer Res.
17:4942–4947. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Castells M, Thibault B, Delord JP and
Couderc B: Implication of tumor microenvironment in
chemoresistance: Tumor-associated stromal cells protect tumor cells
from cell death. Int J Mol Sci. 13:9545–9571. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hanahan D and Coussens LM: Accessories to
the crime: Functions of cells recruited to the tumor
microenvironment. Cancer Cell. 21:309–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scheffer GL, Wijngaard PL, Flens MJ,
Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC and
Scheper RJ: The drug resistance-related protein LRP is the human
major vault protein. Nat Med. 1:578–582. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kerr EH, Frederick PJ, Egger ME, Stockard
CR, Sellers J, DellaManna D, Oelschlager DK, Amm HM, Eltoum IE,
Straughn JM, et al: Lung resistance-related protein (LRP)
expression in malignant ascitic cells as a prognostic marker for
advanced ovarian serous carcinoma. Ann Surg Oncol. 20:3059–3065.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen ZJ, Le HB, Zhang YK, Qian LY, Sekhar
KR and Li WD: Lung resistance protein and multidrug resistance
protein in non-small cell lung cancer and their clinical
significance. J Int Med Res. 39:1693–1700. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han M, Lv Q, Tang XJ, Hu YL, Xu DH, Li FZ,
Liang WQ and Gao JQ: Overcoming drug resistance of MCF-7/ADR cells
by altering intracellular distribution of doxorubicin via MVP
knockdown with a novel siRNA polyamidoamine-hyaluronic acid
complex. J Control Release. 163:136–144. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kedersha NL, Hill DF, Kronquist KE and
Rome LH: Subpopulations of liver coated vesicles resolved by
preparative agarose gel electrophoresis. J Cell Biol. 103:287–297.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kickhoefer VA, Searles RP, Kedersha NL,
Garber ME, Johnson DL and Rome LH: Vault ribonucleoprotein
particles from rat and bullfrog contain a related small RNA that is
transcribed by RNA polymerase III. J Biol Chem. 268:7868–7873.
1993.PubMed/NCBI
|
|
27
|
Kickhoefer VA, Siva AC, Kedersha NL, Inman
EM, Ruland C, Streuli M and Rome LH: The 193-kD vault protein,
VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol.
146:917–928. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kickhoefer VA, Stephen AG, Harrington L,
Robinson MO and Rome LH: Vaults and telomerase share a common
subunit, TEP1. J Biol Chem. 274:32712–32717. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Izquierdo MA, Scheffer GL, Flens MJ,
Giaccone G, Broxterman HJ, Meijer CJ, van der Valk P and Scheper
RJ: Broad distribution of the multidrug resistance-related vault
lung resistance protein in normal human tissues and tumors. Am J
Pathol. 148:877–887. 1996.PubMed/NCBI
|
|
30
|
List AF, Spier CS, Grogan TM, Johnson C,
Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ
and Dalton WS: Overexpression of the major vault transporter
protein lung-resistance protein predicts treatment outcome in acute
myeloid leukemia. Blood. 87:2464–2469. 1996.PubMed/NCBI
|
|
31
|
Henríquez-Hernández LA, Moreno M, Rey A,
Lloret M and Lara PC: MVP expression in the prediction of clinical
outcome of locally advanced oral squamous cell carcinoma patients
treated with radiotherapy. Radiat Oncol. 7:1472012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB
and Li XQ: Association of expression of MRP1, BCRP, LRP and ERCC1
with outcome of patients with locally advanced non-small cell lung
cancer who received neoadjuvant chemotherapy. Lung Cancer.
69:116–122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu S, Pardini B, Cheng B, Naccarati A,
Huhn S, Vymetalkova V, Vodickova L, Buchler T, Hemminki K, Vodicka
P and Försti A: Single nucleotide polymorphisms within interferon
signaling pathway genes are associated with colorectal cancer
susceptibility and survival. PLoS One. 9:e1110612014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bosó V, Herrero MJ, Santaballa A, Palomar
L, Megias JE, de la Cueva H, Rojas L, Marqués MR, Poveda JL,
Montalar J and Aliño SF: SNPs and taxane toxicity in breast cancer
patients. Pharmacogenomics. 15:1845–1858. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Du Y, Su T, Zhao L, Tan X, Chang W, Zhang
H and Cao G: Associations of polymorphisms in DNA repair genes and
MDR1 gene with chemotherapy response and survival of non-small cell
lung cancer. PLoS One. 9:e998432014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mendoza J, Martínez J, Hernández C,
Pérez-Montiel D, Castro C, Fabián-Morales E, Santibáñez M,
González-Barrios R, Díaz-Chávez J, Andonegui MA, et al: Association
between ERCC1 and XPA expression and polymorphisms and the response
to cisplatin in testicular germ cell tumours. Br J Cancer.
109:68–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cannistra SA, Matulonis UA, Penson RT,
Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D,
Wenham R and McGuire W: Phase II study of bevacizumab in patients
with platinum-resistant ovarian cancer or peritoneal serous cancer.
J Clin Oncol. 25:5180–5186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ye S, Dhillon S, Ke X, Collins AR and Day
IN: An efficient procedure for genotyping single nucleotide
polymorphisms. Nucleic Acids Res. 29:E88–E89. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Little S: ARMS analysis of point
mutations. Laboratory Methods for the Detection of Mutations and
Polymorphisms in DNA. Taylor GR: CRC Press. 45–51. 1997.
|
|
40
|
Shi YY and He L: SHEsis, a powerful
software platform for analyses of linkage disequilibrium, haplotype
construction and genetic association at polymorphism loci. Cell
Res. 15:97–98. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mutch DG and Prat J: 2014 FIGO staging for
ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol.
133:401–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Filipits M, Pohl G, Stranzl T, Suchomel
RW, Scheper RJ, Jäger U, Geissler K, Lechner K and Pirker R:
Expression of the lung resistance protein predicts poor outcome in
de novo acute myeloid leukemia. Blood. 91:1508–1513.
1998.PubMed/NCBI
|
|
43
|
Szaflarski W, Sujka-Kordowska P, Pula B,
Jaszczyńska-Nowinka K, Andrzejewska M, Zawierucha P, Dziegiel P,
Nowicki M, Ivanov P and Zabel M: Expression profiles of vault
components MVP, TEP1 and vPARP and their correlation to other
multidrug resistance proteins in ovarian cancer. Int J Oncol.
43:513–520. 2013.PubMed/NCBI
|
|
44
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Goff BA, Paley PJ, Greer BE and Gown AM:
Evaluation of chemoresistance markers in women with epithelial
ovarian carcinoma. Gynecol Oncol. 81:18–24. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sedláková I, Laco J, Caltová K, Červinka
M, Tošner J, Řezáč A and Špaček J: Clinical significance of the
resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in
epithelialovarian cancer. Int J Gynecol Cancer. 25:236–243. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mossink MH, van Zon A, Fränzel-Luiten E,
Schoester M, Kickhoefer VA, Scheffer GL, Scheper RJ, Sonneveld P
and Wiemer EA: Disruption of the murine major vault protein
(MVP/LRP) gene does not induce hypersensitivity to cytostatics.
Cancer Res. 62:7298–7304. 2002.PubMed/NCBI
|
|
48
|
van Zon A, Mossink MH, Schoester M,
Scheper RJ, Sonneveld P and Wiemer EAC: Efflux kinetics and
intracellular distribution of daunorubicin are not affected by
major vault protein/lung resistance-related protein (vault)
expression. Cancer Res. 64:4887–4892. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Huffman KE and Corey DR: Major vault
protein does not play a role in chemoresistance or drug
localization in a non-small cell lung cancer cell line.
Biochemistry. 44:2253–2261. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Balan S, Radhab SK, Sathyan S, Vijai J,
Banerjee M and Radhakrishnan K: Major vault protein (MVP) gene
polymorphisms and drug resistance in mesial temporal lobe epilepsy
with hippocampal sclerosis. Gene. 526:449–453. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Siva AC, Raval-Fernandes S, Stephen AG,
LaFemina MJ, Scheper RJ, Kickhoefer VA and Rome LH: Up-regulation
of vaults may be necessary but not sufficient for multidrug
resistance. Int J Cancer. 92:195–202. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yu Z, Fotouhi-Ardakani N, Wu L, Maoui M,
Wang S, Banville D and Shen SH: PTEN associates with the vault
particles in HeLa cells. J Biol Chem. 277:40247–40252. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Steiner E, Holzmann K, Pirker C, Elbling
L, Micksche M, Sutterlüty H and Berger W: The major vault protein
is responsive to and interferes with interferon-gamma-mediated
STAT1 signals. J Cell Sci. 119:459–469. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Losert A, Lötsch D, Lackner A,
Koppensteiner H, Peter-Vörösmarty B, Steiner E, Holzmann K, Grunt
T, Schmid K, Marian B, et al: The major vault protein mediates
resistance to epidermal growth factor receptor inhibition in human
hepatoma cells. Cancer Lett. 319:164–172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lötsch D, Steiner E, Holzmann K,
Spiegl-Kreinecker S, Pirker C, Hlavaty J, Petznek H, Hegedus B,
Garay T, Mohr T, et al: Major vault protein supports glioblastoma
survival and migration by upregulating the EGFR/PI3K signalling
axis. Oncotarget. 4:1904–1918. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tomiyasu H, Watanabe M, Goto-Koshino Y,
Fujino Y, Ohno K, Sugano S and Tsujimoto H: Regulation of
expression of ABCB1 and LRP genes by mitogen-activated protein
kinase/extracellular signal-regulated kinase pathway and its role
in generation of side population cells in canine lymphoma cell
lines. Leuk Lymphoma. 54:1309–1315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Rivera-Rivera L, Perez-Laspiur J, Colón K
and Meléndez LM: Inhibition of interferon response by cystatin B:
Implication in HIV replication of macrophage reservoirs. J
Neurovirol. 18:20–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liu S, Peng N, Xie J, Hao Q, Zhang M,
Zhang Y, Xia Z, Xu G, Zhao F, Wang Q, et al: Human hepatitis B
virus surface and e antigens inhibit major vault protein signaling
in interferon induction pathways. J Hepatol. 62:1015–1023. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Liu S, Hao Q, Peng N, Yue X, Wang Y, Chen
Y, Wu J and Zhu Y: Major vault protein: A virus-induced host factor
against viral replication through the induction of type-I
interferon. Hepatology. 56:57–66. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Dortet L, Mostowy S, Samba-Louaka A, Gouin
E, Nahori MA, Wiemer EA, Dussurget O and Cossart P: Recruitment of
the major vault protein by InlK: A Listeria monocytogenes strategy
to avoid autophagy. PLoS Pathog. 7:e10021682011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Etlik O, Koksal V, Arican-Baris ST and
Baris I: Development and validation of a cost-effective in-house
method, tetra-primer ARMS PCR assay, in genotyping of seven
clinically important point mutations. Mol Cell Probes. 25:177–181.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Miranzadeh-Mahabadi H, Miranzadeh-Mahabadi
H, Nikpour P, Emadi-Baygi M and Kelishadi R: Comparison of TaqMan
real-time and tetra-primer ARMS PCR techniques for genotyping of Rs
8066560 variant in children and adolescents with metabolic
syndrome. Adv Clin Exp Med. 24:951–955. 2015. View Article : Google Scholar : PubMed/NCBI
|
